It all started earlier this year when German pharmaceutical company, Bayer, petitioned the FDA about changing the labeling on its aspirin in order to market aspirin as a means for preventing heart attacks in people who have not had cardiovascular disease.

It’s no wonder Bayer would like more of us using their drug on a daily basis since in 2013 alone, aspirin generated $1.27 billion in sales for Bayer.[1]

But the FDA took a long hard look …